文献速递前列腺癌

恩杂鲁胺联合雄激素剥夺治疗与挽救性放疗在高危PSA复发前列腺癌中的II期试验:STREAM试验

Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.
PubMed 文献 · Eur Urol Oncol · 2020-02-13

STREAM是一项三中心前瞻性II期单臂试验,纳入38例根治性前列腺切除术后4年内PSA复发、Gleason 7-10分、无转移证据且未接受过激素治疗的前列腺癌患者,接受6个月ADT联合恩杂鲁胺160mg/d及66Gy挽救性放疗。主要终点2年PFS为65%(95%CI 47-78),3年PFS为53%,29%患者出现G3毒性,无G4-5或意外毒性,生活质量在3个月时轻度恶化但24个月时多数恢复。结论认为该方案安全且疗效令人鼓舞,值得开展III期对照试验。

要点

  • 高危PSA复发前列腺癌患者接受恩杂鲁胺+ADT+挽救性放疗,2年PFS达65%。
  • 3年PFS为53%,G3毒性发生率29%,无G4-5或意外毒性。
  • 生活质量在3个月时轻度恶化,24个月时多数患者恢复。

核心结论

  • 根治性前列腺切除术后PSA复发的高危前列腺癌患者,接受挽救性放疗联合恩杂鲁胺和ADT是安全的,并显示出令人鼓舞的疗效,值得开展前瞻性对照III期试验。

研究设计与样本

  • 三中心前瞻性II期单臂试验(NCT02057939),纳入38例Gleason 7-10分、根治性前列腺切除术后4年内PSA复发(0.2-4.0 ng/dl)、无既往激素治疗且无影像学转移证据的前列腺癌患者,37例完成治疗并可评估2年睾酮恢复。

主要发现

  • 主要终点2年PFS为65%(95%CI 47-78),历史对照(类似入组标准接受挽救性放疗联合辅助多西他赛的试验)为51%(95%CI 33-67)。
  • 3年PFS为53%。
  • 生活质量数据显示3个月时肠道、膀胱和激素相关症状轻度恶化,24个月时多数患者恢复。

关键数值与推荐

  • 干预措施:6个月ADT联合恩杂鲁胺160 mg/d口服每日一次,以及前列腺床66 Gy放疗。
  • 主要终点:2年PFS较历史对照改善。

临床怎么用

  • 对于根治性前列腺切除术后PSA复发的高危前列腺癌患者,可考虑在挽救性放疗和ADT基础上联合恩杂鲁胺,但需在III期试验证实前谨慎评估获益与风险。

局限性

  • 单臂II期试验,样本量小(38例),主要终点为与历史对照比较,非随机对照,证据级别有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Salvage external beam radiotherapy (RT) with androgen deprivation therapy (ADT) improves survival over RT in men with prostate cancer (PC) and rising prostate-specific antigen (PSA) levels after radical prostatectomy (RP). OBJECTIVE: To investigate the safety and efficacy of enzalutamide concurrent with salvage RT and ADT. DESIGN, SETTING, AND PARTICIPANTS: This was a three-center prospective phase 2 single-arm trial (NCT02057939) of men with Gleason 7-10 PC and PSA recurrence within 4 yr of RP ranging from 0.2 to 4.0 ng/dl, no prior hormonal therapy, and no radiographic evidence of metastases. We enrolled 38 men; 37 completed therapy and were evaluable with testosterone recovery at 2 yr. INTERVENTION: Six months of ADT with 160 mg/d enzalutamide and 66 Gy RT to the prostate bed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was improved 2-yr progression-free survival (PFS) over historical controls. Secondary objectives included 3-yr PFS, safety, and patient-reported quality of life (QOL). RESULTS AND LIMITATIONS: The primary endpoint of 2-yr PFS was 65% (95% confidence interval [CI]: 47, 78) versus 51% (95% CI: 33, 67) in a trial of men with similar eligibility treated with salvage RT and adjuvant docetaxel. The 3-yr PFS was 53%. Eleven (29%) men experienced G3 toxicities, and there were no G4-5 or unexpected toxicities. QOL data suggest modest worsening of bowel, bladder, and hormonal symptoms at 3 mo, with recovery by 24 mo in most men. CONCLUSIONS: Salvage RT with enzalutamide and ADT following RP for men with PSA recurrent high-risk PC is safe and demonstrates encouraging efficacy, warranting prospective controlled phase 3 trials of ADT with or without potent androgen receptor inhibition in this curative-intent setting. PATIENT SUMMARY: Addition of 6 mo of oral daily enzalutamide to standard salvage radiation and hormone therapy is safe and may improve prostate cancer remission rates at 2 and 3 yr.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Bitting RL, Healy P, George DJ, et al. Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial. Eur Urol Oncol. 2020. PMID: 32063492. doi:10.1016/j.euo.2020.01.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。